Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting ...
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...
RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval ...
Health on MSN2h
Everything You Need To Know About Liver FibrosisLiver fibrosis is the build up of scar tissue in the liver when it tries to heal itself. Symptoms may include fatigue, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback